Signalpoint

← Full daily brief

Mass Tort brief

Tylenol and Social Media Litigation Rebound

A landmark appellate ruling revives Tylenol autism lawsuits as tech giants appeal youth addiction verdicts.

Signalpoint TeamBrief

Mass Tort

A federal appeals court revived over 550 Tylenol autism lawsuits by restricting a judge's power to reject scientific experts — returning leverage to plaintiffs and forcing Kenvue toward a costly settlement.

BackgroundUnder Federal Rule of Evidence 702, district judges act as gatekeepers to ensure scientific expert testimony is reliable before reaching a jury. The consolidated Tylenol multidistrict litigation was dismissed in 2023 when the trial judge ruled the plaintiffs' science was unreliable.

Points
  1. Judge Guido Calabresi ruled that the district judge overstepped her gatekeeping role by resolving scientific disputes herself, meaning a jury must now evaluate the competing scientific studies.
  2. The procedural decision reopens the consolidated multidistrict litigation, returning the active cases to the Southern District of New York for immediate pretrial proceedings.
  3. Tylenol maker Kenvue emphasized that the procedural ruling does not establish a scientific link, attempting to reassure investors and mitigate the immediate stock market fallout.
SourcesKenvue: Second Circuit Court of Appeals Ruling (opens in new tab)JURIST: US appeals court reverses dismissal of Tylenol cases (opens in new tab)

Mass Tort

YouTube and Meta are fighting a $6M youth addiction verdict — if their appeal fails, tech platforms could face massive liabilities for standard design features like infinite scroll.

BackgroundTech platforms enjoy broad liability protections under Section 230 of the Communications Decency Act for third-party content. However, plaintiffs' attorneys are increasingly targeting the platforms' native design features, such as autoplay and infinite scroll, as addictive design defects.

Points
  1. The jury apportioned liability as 70% for Meta and 30% for YouTube, creating a legal precedent that lets plaintiffs target multiple platforms simultaneously for shared harm.
  2. The trial serves as a key bellwether, meaning a loss on appeal could greenlight over 20 similar trials currently pending in other state and federal jurisdictions.
  3. Tech defense lawyers argue that features like autoplay are protected editorial choices, warning that upholding the verdict would destroy Section 230 protections for digital product design.
SourcesAP News: YouTube appeals jury verdict in social media addiction lawsuit (opens in new tab)

Mass Tort

Philips began paying out its $1.075B settlement for toxic CPAP machines — clearing a massive legal overhang and establishing a structured model for resolving the remaining global claims.

BackgroundPhilips recalled 5.5 million CPAP and BiPAP devices in 2021 due to toxic polyester-based sound-abatement foam that degraded and could be inhaled by users. The litigation involved thousands of claims alleging respiratory injuries, cancer, and death.

Points
  1. The settlement resolves a massive block of personal injury and wrongful death lawsuits, allowing Philips to finally clear a major legal overhang that has depressed its stock.
  2. Philips continues to deny all liability as part of the deal, protecting itself from criminal admissions even as it pays out billions to resolve the civil claims.
  3. Payments will flow through an independent administrator using a structured tier system, ensuring that patients with severe respiratory diagnoses receive the largest financial shares.
SourcesThe Legal Examiner: Philips CPAP Settlement Update: Payments Begin (opens in new tab)

Mass Tort

A new study linking progesterone contraceptives to brain tumors provides crucial ammunition for state-level lawsuits — putting pressure on Pfizer to expand its tentative federal settlement.

BackgroundDepo-Provera is a highly popular contraceptive injection that uses synthetic progesterone to prevent pregnancy. Recent studies linking the drug to intracranial meningiomas have triggered mass tort litigation across several federal and state court systems.

Points
  1. The federal multidistrict litigation remains frozen under a tentative global class settlement proposed by Pfizer, meaning the new study cannot be used to renegotiate those federal terms.
  2. Over 100 state-level cases in Delaware are unaffected by the federal freeze, allowing plaintiffs to use this new data to push their cases forward to active trials.
  3. Plaintiffs' lawyers plan to submit the Danish study during upcoming expert hearings, hoping to defeat Pfizer's attempts to throw out the state cases on scientific reliability grounds.
SourcesAboutLawsuits.com: New Study Adds to Evidence Depo-Provera Injections Cause Meningioma Brain Tumor Risks (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.